Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal
Bitget2026/09/28 10:46- Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor.
- Deal grants worldwide rights to develop, manufacture, commercialize SPR2015.
- SciBrunch to receive USD 400 million upfront.
- Milestone payments could lift total potential deal value to USD 2.13 billion across multiple indications.
- Merck expects a USD 400 million pre-tax charge in Q3 2026, about USD 0.13 per share.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
